Filing Details
- Accession Number:
- 0001415889-25-019321
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-07-03 16:21:24
- Reporting Period:
- 2025-07-01
- Filing Date:
- 2025-07-03
- Accepted Time:
- 2025-07-03 16:21:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1671858 | Ars Pharmaceuticals Inc. | SPRY | Pharmaceutical Preparations (2834) | 811489190 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1951287 | Eric Karas | C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130 | Chief Commercial Officer | No | No | No | No |
Transaction Summary
| Sold: | 15,000 shares | Avg. Price: $16.99 | Total Value: $254,860.50 |
| Number of Shares After Transactions: | 10,315 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-07-01 | 15,000 | $1.50 | 25,315 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-07-01 | 15,000 | $16.99 | 10,315 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-07-01 | 15,000 | $0.00 | 15,000 | $1.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 544,588 | 2032-05-23 | No | 4 | M | Direct |
Footnotes
- Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- Immediately exercisable.
Billionaire Hedge Funds
